This site is intended for health professionals only

Published on 22 April 2009

Share this story:
Twitter
LinkedIn

Roche and Genentech remain committed to Avastin adjuvant programs

teaser

Phase III C-08 study of Avastin in early-stage colon cancer does not meet primary endpoint
Roche and Genentech remain committed to Avastin adjuvant programs

Roche today announced the results of the first phase III trial evaluating the use of Avastin (bevacizumab) plus
chemotherapy (FOLFOX) for the treatment of colon cancer immediately following surgery (adjuvant therapy) compared to chemotherapy alone.

The study, known as NSABP C-08, did not meet its primaryendpoint of lowering the risk of the cancer returning (disease-free survival).

This is the first trial of Avastin in early-stage cancer and results do not affect approved indications in advanced (metastatic) disease.

Safety findings were consistent with those presented from this study at the 2008 American Society of Clinical Oncology (ASCO) annual meeting (Allegra et al).

“While we are disappointed the C-08 study did not meet its primary endpoint, our initial review of the data leads us to continue to believe Avastin may be active in patients with early-stage colon cancer and look forward to NSABP’s presentation at ASCO,” said Hal Barron, senior vice president, Development and chief medical officer, Genentech.

“We remain fully committed to the ongoing Avastin adjuvant programs in early-stage colon, breast and lung cancers.”
“In order to provide patients with the full potential benefit of Avastin in early-stage cancer, we believe the findings of the C-08 trial should be considered for the ongoing adjuvant trial programs,“ said William M Burns, CEO of Roche’s Pharmaceuticals Division.

“The current studies and indications in advanced disease
are not affected.”

Roche



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn